In vitro metabolism of trazodone by CYP3A: Inhibition by ketoconazole and human immunodeficiency viral protease inhibitors

Biological Psychiatry

Volumn 47, Issue 7, 2000, Pages 655-661

  Zalma, Alysa ^a,b   Von Moltke, Lisa L ^a,b   Granda, Brian W ^a,b   Harmatz, Jerold S ^a,b   Shader, Richard I ^a,b   Greenblatt, David J ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

CYP3A; Ketoconazole; m chlorophenylpiperazine; Trazodone; Viral protease inhibitors

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ANTIFUNGAL AGENT; CYTOCHROME P450 3A; DRUG METABOLITE; INDINAVIR; KETOCONAZOLE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRAZODONE;

AFFECTIVE NEUROSIS; ARTICLE; BIOTRANSFORMATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME KINETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; KETOCONAZOLE; MICROSOMES, LIVER; NELFINAVIR; OXIDOREDUCTASES, N-DEMETHYLATING; PIPERAZINES; RITONAVIR; SAQUINAVIR; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; TRAZODONE;

EID: 0034177465     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00176-6     Document Type: Article

References (52)

1. Baiocchi L., Frigerio A. Basic metabolites of trazodone in humans. Arzneimittelforschung. 24:1974;1699-1706.
2. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokin. 32:1997;194-209.
3. Barry M., Mulcahy F., Back D.J. Antiretroviral therapy for patients with HIV disease. Br J Clin Pharmacol. 45:1998;221-228.
4. Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 32:1997;210-258.
5. Bluestine S., Lesko L. Psychotropic medications in oncology and in AIDS patients. Adv Psychosom Med. 21:1994;107-137.
6. Brogden R.N., Heel R.C., Speight T.M., Avery G.S. Trazodone A review of its pharmacological properties and therapeutic use in depression and anxiety . Drugs. 21:1981;401-429.
7. Carpenter C.C.J., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., et al. Antiretroviral therapy for HIV infection in 1998 Updated recommendations of the International AIDS Society-USA Panel . JAMA. 280:1998;78-86.
8. Como J.A., Dismukes W.E. Oral azole drugs as systemic antifungal therapy. N Engl J Med. 330:1994;263-272.
9. Crespi C. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res. 26:1995;179-235.
10. Crespi C.L., Penman B.W. Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol. 43:1997;71-188.
11. Darko D.F., McCutchan J.A., Kripke D.F., Gillin J.C., Golshan S. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. Am J Psychiatry. 149:1992;514-520.
12. Eagling V.A., Back D.J., Barry M.G. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 44:1997;190-194.
13. Flexner C. HIV-protease inhibitors. N Engl J Med. 338:1998;1281-1292.
14. Georgotas A., Forsell T.L., Mann J.J., Kim M., Gershon S. Trazodone hydrochloride A wide spectrum antidepressant with a unique pharmacological profile. A review of its neurochemical effects, pharmacology, clinical efficacy, and toxicology . Pharmacotherapy. 2:1982;255-265.
15. Ghahramani P., Ellis S.W., Lennard M.S., Ramsay L.E., Tucker G.T. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 43:1997;137-144.
16. Grant I. The neuropsychiatry of human immunodeficiency virus. Semin Neurol. 10:1990;267-275.
17. Greenblatt DJ, von Moltke LL (1997): Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori W, editor. Drug-Drug Interactions: Analyzing In Vitro-In Vivo Correlations. Southboro MA: International Business Communications, pp 2.2.1-2.2.28.
18. Greenblatt D.J., von Moltke L.L., Daily J.P., Harmatz J.S., Shader R.I. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir The clinical dilemma of concurrent inhibition and induction . J Clin Psychopharmacol. 19:1999;293-296.
19. Greenblatt D.J., von Moltke L.L., Harmatz J.S., Mertzanis P., Graf J.A., Durol A.L.B., et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther. 64:1998;661-671.
20. Greenblatt D.J., Wright C.E., von Moltke L.L., Harmatz J.S., Ehrenberg B.L., Harrel L.M., et al. Ketoconazole inhibition of triazolam and alprazolam clearance Differential kinetic and dynamic consequences . Clin Pharmacol Ther. 64:1998;237-247.
21. Harlow G.R., Halpert J.R. Analysis of human cytochrome P450 3A4 cooperativity Construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics . Proc Natl Acad Sci U S A. 95:1998;6636-6641.
22. Hsu A., Granneman G.R., Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 35:1998;275-291.
23. Inaba T., Fischer N.E., Riddick D.S., Stewart D.J., Hidaka T. HIV protease inhibitors, saquinavir, indinavir, ritonavir Inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes . Toxicol Lett. 93:1997;215-219.
24. Iribarne C., Berthou F., Carlhant D., Dreano Y., Picart D., Lohezic F., et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos. 26:1998;257-260.
25. Ishida M., Otani K., Kaneko S., Ohkubo T., Osanai T., Yasui N., et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol. 10:1995;143-146.
26. Jauch V.R., Kopitar Z., Prox A., Zimmer A. Pharmakokinetik und Stoffwechsel von Trazodone beim Menschen. Arzneimittelforschung. 26:1976;2084-2089.
27. Koudriakova T., Iatsimirskaia E., Utkin I., Gangl E., Vouros P., Storozhuk E., et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5 Mechanism-based inactivation of cytochrome P4503A by ritonavir . Drug Metab Dispos. 26:1998;552-561.
28. Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 277:1996;423-431.
29. Ludden T.M., Beal S.L., Sheiner L.B. Comparison of the Akaike Information Criterion, the Schwarz Criterion and the F Test as guides to model selection. J Pharmacokinet Biopharm. 22:1994;431-445.
30. Moyle G.J., Gazzard B.G., Cooper D.A., Gatell J. Antiretroviral therapy for HIV infection. Drugs. 55:1998;383-404.
31. Obach R.S. Nonspecific binding to microsomes. Drug Metab Dispos. 25:1997;1359-1369.
32. Rotzinger S., Fang J., Baker G.B. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 26:1998;572-575.
33. Schmider J., Greenblatt D.J., Harmatz J.S., Shader R.I. Enzyme kinetic modeling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions Application to amitriptyline N-demethylation . Br J Clin Pharmacol. 41:1996;593-604.
34. Schwab G.E., Raucy J.L., Johnson E.F. Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by α-naphthoflavone. Mol Pharmacol. 33:1988;493-499.
35. Shou M., Grogan J., Mancewicz J.A., Krausz K.W., Gonzalez F.J., Gelboin H.V., et al. Activation of CYP3A4 Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site . Biochemistry. 33:1994;6450-6455.
36. Snyder S., Strain J.J., Fulop G. Evaluation and treatment of mental disorders in patients with AIDS. Compr Ther. 16:1990;34-41.
37. Ueng Y.-F., Kuwabara T., Chun Y.-J., Guengerich F. Cooperativity in oxidations catalyzed by cytochrome P450-3A4. Biochemistry. 36:1997;370-381.
38. van Gorp W.G., Buckingham S.L. Practitioner's Guide to the Neuropsychiatry of HIV/AIDS. 1998;The Guilford Press, New York.
39. Venkatakrishnan K., Greenblatt D.J., von Moltke L.L., Schmider J., Harmatz J.S., Shader R.I. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro Dominance of CYP 2C19 and 3A4 . J Clin Pharmacol. 38:1998;112-121.
40. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Duan S.X., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole A model system to predict drug interactions in vivo . J Pharmacol Exp Ther. 268:1994;1278-1283.
41. von Moltke L.L., Greenblatt D.J., Cotreau-Bibbo M.M., Harmatz J.S., Shader R.I. Inhibitors of alprazolam metabolism in vitro Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine . Br J Clin Pharmacol. 38:1994;23-31.
42. von Moltke L.L., Greenblatt D.J., Duan S.X., Daily J.P., Harmatz J.S., Shader R.I. Inhibition of desipramine hydroxylation (cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors Relation to drug interactions in vivo . J Pharm Sci. 87:1998;1184-1189.
43. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Duan S.X., Harrel L.M., Cotreau-Bibbo M.M., et al. Triazolam biotransformation by human liver microsomes in vitro Effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole . J Pharmacol Exp Ther. 276:1996;370-379.
44. von Moltke L.L., Greenblatt D.J., Granda B.W., Grassi J.M., Schmider J., Harmatz J.S., et al. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro Cytochromes mediating transformation, and P450-3A4 inhibitory actions . Psychopharmacology. 145:1999;113-122.
45. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M., et al. Protease inhibitors as inhibitors of human cytochromes P450 High risk associated with ritonavir . J Clin Pharmacol. 38:1998;106-111.
46. von Moltke L.L., Greenblatt D.J., Harmatz J.S., Shader R.I. Alprazolam metabolism in vitro Studies of human, monkey, mouse, and rat liver microsomes . Pharmacology. 47:1993;268-276.
47. von Moltke L.L., Greenblatt D.J., Schmider J., Duan S.X., Wright C.E., Harmatz J.S., et al. Midazolam hydroxylation by human liver microsomes in vitro Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents . J Clin Pharmacol. 36:1996;783-791.
48. von Moltke L.L., Greenblatt D.J., Schmider J., Harmatz J.S., Shader R.I. Metabolism of drugs by cytochrome P450 3A isoforms Implications for drug interactions in psychopharmacology . Clin Pharmacokinet. 29:(suppl 1):1995;33-43.
49. von Moltke L.L., Greenblatt D.J., Schmider J., Wright C.E., Harmatz J.S., Shader R.I. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol. 55:1998;113-122.
50. von Moltke L.L., Zalma A., Granda B.W., Grassi J.M., Shader R.I., Greenblatt D. Meta-chloro-phenylpiperazine (mCPP) P450-3A-dependent formation from nefazodone and trazodone; P450-2D6-dependent clearance (abstract) . Clin Pharmacol Ther. 65:1999;144.
51. Wrighton S.A., Ring B.J. Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine. Pharm Res. 11:1994;921-924.
52. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 6:1978;165-175.